Loading
T030 is the belotecan-derived topoisomerase payload in sacituzumab tirumotecan, designed to be less affected by the pumps that eject SN-38.
T030 is a camptothecin analogue derived from belotecan. Kelun and MSD report weaker efflux-pump susceptibility than SN-38 and a more stable linker, which may translate into a different resistance and toxicity profile within the same mechanistic class. Evidence comes largely from sponsor data and Chinese trials, so treat cross-class comparisons as provisional.
Sac-TMT carries T030, a belotecan-derived TOP1 inhibitor; belotecan shown.
Showing the molecule this term concerns: Sacituzumab tirumotecan.
Shares Topoisomerase-I inhibitor payloads, Drug efflux pumps (ABC transporters), Payload (ADC), Topoisomerase-I inhibitors (and ADC payloads).
Shares Topoisomerase-I inhibitor payloads, Drug efflux pumps (ABC transporters), Payload (ADC), Topoisomerase-I inhibitors (and ADC payloads).
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Topoisomerase-I inhibitor payloads, Payload (ADC), Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).